Windlas Biotech posts single-digit growth numbers in Q1FY23; stock slips ~2%

5 Aug 2022 , 03:13 PM

Windlas Biotech Limited, one of India’s top five players in the domestic pharmaceutical formulations CDMO industry, released its audited financials for the quarter ended June 30, 2022.

Company’s consolidated revenue from operations stood at Rs119.9 crore in Q1FY23 as compared to Rs111 crore in Q1FY22, clocking a growth of 8.1% yoy.

Consolidated EBITDA came in at Rs13.8 crore in Q1FY23 as compared to Rs12.4 crore in Q1FY22, up by 11.4% on a y-o-y basis. It achieved an EBITDA Margin of 11.5%.

PAT stood at Rs9.80 crore in Q1FY23 as compared to Rs6.7 crore in the previous corresponding quarter, registering a growth of 46.6% yoy. PAT Margin for Q1FY23 came in at 8.2%.

Windlas’ Q1FY23 revenue for the CDMO vertical remained largely stable at Rs94.8 crore, contributing about 79% of the consolidated revenue. While Q1FY23 revenue for the Trade Generics vertical was reported at Rs21.4 crore, up 73.2% yoy, contributing about 18% of consolidated revenue.

Exports vertical contributed approximately 2% for Q1FY23 to the consolidated revenue.

CDMO and Export verticals registered a decline of 0.9% and 12.6% yoy in revenue for Q1FY23, respectively.

At around 3.15 PM, Windlas was trading 1.97% lower at Rs217, against previous close of Rs221.35 on NSE. So far, it hit intraday high and low of Rs224.50 and Rs217 respectively.